company background image
CXF logo

Chimerix DB:CXF Stock Report

Last Price

€7.48

Market Cap

€694.7m

7D

-0.7%

1Y

777.9%

Updated

22 Apr, 2025

Data

Company Financials +

Chimerix, Inc.

DB:CXF Stock Report

Market Cap: €694.7m

CXF Stock Overview

A biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases in the United States. More details

CXF fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Rewards

Revenue is forecast to grow 56.38% per year

Risk Analysis

Makes less than USD$1m in revenue ($212K)

Highly volatile share price over the past 3 months compared to the German market

Currently unprofitable and not forecast to become profitable over the next 3 years


Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Chimerix, Inc. Competitors

Biotest

XTRA:BIO3

€1.4b

Formycon

XTRA:FYB

€408.8m

Heidelberg Pharma

XTRA:HPHA

€138.4m

4SC

DB:VSC

€27.3m

Price History & Performance

Summary of share price highs, lows and changes for Chimerix
Historical stock prices
Current Share PriceUS$7.48
52 Week HighUS$7.92
52 Week LowUS$0.66
Beta-0.18
1 Month Change-3.86%
3 Month Change101.89%
1 Year Change777.93%
3 Year Change70.50%
5 Year Change441.83%
Change since IPO-46.71%

Recent News & Updates

Recent updates

Shareholder Returns

CXFDE BiotechsDE Market
7D-0.7%1.2%2.5%
1Y777.9%-14.9%14.4%

Return vs Industry: CXF exceeded the German Biotechs industry which returned -12.8% over the past year.

Return vs Market: CXF exceeded the German Market which returned 7.6% over the past year.

Price Volatility

Is CXF's price volatile compared to industry and market?
CXF volatility
CXF Average Weekly Movement20.0%
Biotechs Industry Average Movement6.0%
Market Average Movement6.3%
10% most volatile stocks in DE Market12.8%
10% least volatile stocks in DE Market3.1%

Stable Share Price: CXF's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: CXF's weekly volatility has decreased from 32% to 20% over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
200079Mike Andriolewww.chimerix.com

Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases in the United States. Its product pipeline comprising dordaviprone (ONC201), which is in phase 3 clinical-stage development for H3 K27M-mutant diffuse glioma, as well as in phase 2 Investigator Initiated Clinical Trials for multiple oncology studies; and ONC206, a second generation imipridone ClpP agonist and DRD2 antagonist which is in phase 1 clinical trial to treat central nervous systems and other solid tumors. The company also develops ONC212, an imipridone, investigational agonist of the orphan GPCR tumor suppressor GPR132, as well as ClpP, which is in preclinical trial; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of novel coronaviruses.

Chimerix, Inc. Fundamentals Summary

How do Chimerix's earnings and revenue compare to its market cap?
CXF fundamental statistics
Market cap€694.70m
Earnings (TTM)-€76.65m
Revenue (TTM)€183.85k

3,779x

P/S Ratio

-9.1x

P/E Ratio

Is CXF overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CXF income statement (TTM)
RevenueUS$212.00k
Cost of RevenueUS$74.57m
Gross Profit-US$74.36m
Other ExpensesUS$14.03m
Earnings-US$88.39m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.94
Gross Margin-35,076.42%
Net Profit Margin-41,691.98%
Debt/Equity Ratio0%

How did CXF perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/04/22 15:39
End of Day Share Price 2025/04/17 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Chimerix, Inc. is covered by 18 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Geoffrey MeachamBarclays
Jonathan AschoffBrean Capital
Ritu BaralCanaccord Genuity